MX2017008587A - Mirna natural para controlar la expresion de gen y uso del mismo. - Google Patents

Mirna natural para controlar la expresion de gen y uso del mismo.

Info

Publication number
MX2017008587A
MX2017008587A MX2017008587A MX2017008587A MX2017008587A MX 2017008587 A MX2017008587 A MX 2017008587A MX 2017008587 A MX2017008587 A MX 2017008587A MX 2017008587 A MX2017008587 A MX 2017008587A MX 2017008587 A MX2017008587 A MX 2017008587A
Authority
MX
Mexico
Prior art keywords
region
chain sequence
mirna
natural look
mature mirna
Prior art date
Application number
MX2017008587A
Other languages
English (en)
Other versions
MX381947B (es
Inventor
Ohgi Tadaaki
Aoki Eriko
Yoshida Yasuhiko
Kato Shiori
Original Assignee
Bonac Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonac Corp filed Critical Bonac Corp
Publication of MX2017008587A publication Critical patent/MX2017008587A/es
Publication of MX381947B publication Critical patent/MX381947B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona un miRNA de tipo natural caracterizado porque:, el miRNA de tipo natural es un ácido nucleico de cadena sencilla que contiene una región X y una región Y; el término 3' de dicha región X y el término 5' de dicha región Y están enlazados a través de una región de enlace de una estructura no nucleótida; la región X comprende (a) una secuencia de cadena guía o (b) una secuencia de cadena pasajera de un miRNA maduro; en caso de (a), la región Y contiene una secuencia de cadena pasajera de este miRNA maduro; mientras que en caso de (b), la región Y contiene una secuencia de cadena guía de este miRNA maduro, y la secuencia de cadena guía y la secuencia de cadena pasajera forman una estructura de cadena doble.
MX2017008587A 2014-12-27 2015-12-25 Mirna natural para controlar la expresion de gen y uso del mismo. MX381947B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014266918 2014-12-27
JP2015130496 2015-06-29
PCT/JP2015/086378 WO2016104775A1 (ja) 2014-12-27 2015-12-25 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途

Publications (2)

Publication Number Publication Date
MX2017008587A true MX2017008587A (es) 2017-10-20
MX381947B MX381947B (es) 2025-03-11

Family

ID=56150787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008587A MX381947B (es) 2014-12-27 2015-12-25 Mirna natural para controlar la expresion de gen y uso del mismo.

Country Status (14)

Country Link
US (1) US11027023B2 (es)
EP (1) EP3239297B1 (es)
JP (1) JP6471176B2 (es)
KR (1) KR20170098914A (es)
CN (1) CN107109415B (es)
AU (1) AU2015368293B2 (es)
BR (1) BR112017013664A2 (es)
CA (1) CA2971827A1 (es)
ES (1) ES2872527T3 (es)
IL (1) IL252880B (es)
MX (1) MX381947B (es)
RU (1) RU2740032C2 (es)
SG (1) SG11201705223XA (es)
WO (1) WO2016104775A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10612020B2 (en) 2013-12-26 2020-04-07 Tokyo Medical University Artificial mimic miRNA for controlling gene expression, and use of same
CA2935022A1 (en) 2013-12-27 2015-07-02 Bonac Corporation Artificial match-type mirna for controlling gene expression and use therefor
US11142769B2 (en) 2015-03-27 2021-10-12 Bonac Corporation Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability
TWI830693B (zh) 2017-02-06 2024-02-01 日商日產化學工業股份有限公司 單股寡核苷酸
JPWO2018182008A1 (ja) * 2017-03-31 2020-02-06 株式会社ボナック 遺伝子発現制御機能を有する環状型核酸分子
JPWO2019074110A1 (ja) 2017-10-13 2020-12-24 株式会社ボナック 一本鎖核酸分子およびその製造方法
TWI830718B (zh) * 2018-02-09 2024-02-01 日商住友化學股份有限公司 核酸分子之製造方法
US20210054377A1 (en) 2018-03-20 2021-02-25 Tokyo Institute Of Technology Antisense oligonucleotide reduced in toxicity
CN115490768B (zh) * 2021-06-18 2024-11-15 佛山热休生物技术有限公司 Col1a1的表位肽及所述表位肽与热休克蛋白的复合物

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE873543C (de) 1942-10-28 1953-04-16 Basf Ag Verfahren zur Herstellung von hydroxyl- bzw. sulfhydryl-gruppenhaltigen Dicarbaminsaeureestern
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4550163A (en) 1979-02-05 1985-10-29 Abbott Laboratories Ligand analog-irreversible enzyme inhibitor conjugates
US20030232355A1 (en) 1992-05-22 2003-12-18 Isis Pharmaceuticals, Inc. Double-stranded peptide nucleic acids
US5631148A (en) 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement
GB9621367D0 (en) 1996-10-14 1996-12-04 Isis Innovation Chiral peptide nucleic acids
US6197557B1 (en) 1997-03-05 2001-03-06 The Regents Of The University Of Michigan Compositions and methods for analysis of nucleic acids
EP1013770A1 (en) 1998-12-23 2000-06-28 Université Louis Pasteur de Strasbourg Non-viral transfection vector
FR2790757B1 (fr) 1999-03-09 2003-08-01 Bioalliance Pharma Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US6962906B2 (en) 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
DE60216468T2 (de) 2001-03-09 2007-09-27 Boston Probes, Inc., Bedford Kombinationsoligomere betreffende verfahren, kits und zusammensetzungen
AU2004266311B2 (en) 2001-05-18 2009-07-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003037909A1 (en) 2001-10-29 2003-05-08 Mcgill University Acyclic linker-containing oligonucleotides and uses thereof
US20060111312A1 (en) 2002-02-22 2006-05-25 The John Hopkins University Antigene locks and therapeutic uses thereof
WO2003079757A2 (en) 2002-03-20 2003-10-02 Massachusetts Institute Of Technology Hiv therapeutic
BRPI0313202A8 (pt) 2002-08-05 2016-08-16 Atugen Ag Formas adicionais para interferir com as moléculas de rna
WO2004015075A2 (en) * 2002-08-08 2004-02-19 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
US6936651B2 (en) 2002-12-17 2005-08-30 E. I. Du Pont De Nemours And Company Compatibility improvement in crystalline thermoplastics with mineral fillers
EP1608735A4 (en) 2003-04-03 2008-11-05 Alnylam Pharmaceuticals RNAI CONJUGATES
WO2004111072A2 (en) 2003-06-12 2004-12-23 Applera Corporation Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
WO2005030960A1 (ja) 2003-09-30 2005-04-07 Anges Mg, Inc. ステイプル型オリゴヌクレオチドおよびそれからなる医薬
EP1680439A2 (en) 2003-10-14 2006-07-19 Kernel Biopharma Inc. Dual phase-pna conjugates for the delivery of pna through the blood brain barrier
US20050209141A1 (en) 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
EP1789553B1 (en) 2004-06-30 2014-03-26 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a non-phosphate backbone linkage
CN105251024A (zh) 2004-08-23 2016-01-20 西伦蒂斯私人股份公司 眼病的治疗
WO2006022325A1 (ja) 2004-08-26 2006-03-02 Nippon Shinyaku Co., Ltd. ガラクトース誘導体、薬物担体及び医薬組成物
MX2007002423A (es) 2004-08-31 2007-08-07 Sylentis Sau Metodos y composiciones para inhibir la expresion del receptor p2x7.
BRPI0516874A (pt) 2004-10-12 2008-09-23 Univ Rockefeller micrornas
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US20090005332A1 (en) 2004-12-30 2009-01-01 Hauser Todd M Compositions and Methods for Modulating Gene Expression Using Self-Protected Oligonucleotides
EP2003140B1 (en) 2006-03-01 2010-01-20 Nippon Shinyaku Co., Ltd. Galactose derivative, drug carrier and medicinal composition
CA3044969A1 (en) 2006-05-05 2007-12-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
WO2007142755A2 (en) 2006-05-31 2007-12-13 The Regents Of The University Of California Purine analogs
EP1890152A1 (en) 2006-08-14 2008-02-20 Charite Universitätsmedizin-Berlin Determination of renin/prorenin receptor activity
JP2008220366A (ja) 2007-02-16 2008-09-25 National Institute Of Advanced Industrial & Technology 修飾型ｐｎａ／ｒｎａ複合体
JP5145557B2 (ja) 2007-03-01 2013-02-20 財団法人ヒューマンサイエンス振興財団 マイクロｒｎａを有効成分として含有する腫瘍増殖抑制剤、および癌治療用医薬組成物
WO2008116094A2 (en) 2007-03-21 2008-09-25 Brookhaven Science Associates, Llc Combined hairpin-antisense compositions and methods for modulating expression
CN101121934B (zh) 2007-04-11 2011-12-07 哈尔滨医科大学 多靶点miRNA反义核苷酸的制备方法
WO2008137867A2 (en) 2007-05-03 2008-11-13 Rosetta Inpharmatics Llc Compositions comprising mir34 therapeutic agents for treating cancer
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
WO2009023333A2 (en) 2007-05-17 2009-02-19 Baylor College Of Medicine Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines
WO2008147839A1 (en) 2007-05-23 2008-12-04 Dharmacon, Inc. Micro-rna scaffolds and non-naturally occurring micro-rnas
PT2164967E (pt) 2007-05-31 2015-10-27 Univ Iowa Res Found Redução da toxicidade não dirigida do arn de interferência
US20110212075A1 (en) 2007-06-25 2011-09-01 Siemens Aktiengesellschaft Screening method for polymorphic markers in htra1 gene in neurodegenerative disorders
DK2193140T3 (en) * 2007-08-27 2017-01-23 Iglobe Health Inst Llc COMPOSITIONS OF ASYMMETRIC INTERFERRING RNA AND ITS APPLICATIONS
WO2009048932A2 (en) * 2007-10-09 2009-04-16 Children's Medical Center Corporation Methods to regulate mirna processing by targeting lin-28
WO2009047362A2 (en) 2007-10-12 2009-04-16 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Method for opening tight junctions
TW200927177A (en) 2007-10-24 2009-07-01 Nat Inst Of Advanced Ind Scien Lipid-modified double-stranded RNA having potent RNA interference effect
AR069328A1 (es) 2007-11-15 2010-01-13 Alcon Mfg Ltd Liberacion de rna interferente corto o sirna, intermediada por receptor de lipoproteina de baja densidad
US20100317714A1 (en) 2007-11-29 2010-12-16 Suzhou Ribo Life Science Co., Ltd Complex molecule interfering the expression of target genes and its preparing methods
CA2910760C (en) 2007-12-04 2019-07-09 Muthiah Manoharan Targeting lipids
WO2009076321A2 (en) 2007-12-07 2009-06-18 Halo-Bio Rnai Therapeutics Inc. Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides
US20110055965A1 (en) 2008-02-15 2011-03-03 Hiroshi Abe Cycle single-stranded nucleic acid complex and method for producing the same
KR20100131509A (ko) 2008-03-31 2010-12-15 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 Ｒｎａ 간섭 효과가 높은 2본쇄 지질 수식 ｒｎａ
US20110172295A1 (en) 2008-04-11 2011-07-14 The University Of North Carolina At Chapel Hill METHODS AND COMPOSITIONS FOR THE REGULATION OF microRNA PROCESSING
WO2009143619A1 (en) 2008-05-27 2009-12-03 Chum Methods of treating or preventing obesity and obesity-related hypertension
US20100179213A1 (en) 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
JP5794559B2 (ja) * 2008-11-19 2015-10-14 国立大学法人岐阜大学 間葉系細胞の分化を調節するための薬剤及びその利用
US8426581B2 (en) 2009-03-27 2013-04-23 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of the FCεR1α gene
WO2010141511A2 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
EP2454371B1 (en) * 2009-07-13 2021-01-20 Somagenics, Inc. Chemical modification of small hairpin rnas for inhibition of gene expression
EP2456470A1 (en) 2009-07-22 2012-05-30 Cenix Bioscience GmbH Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
US9096850B2 (en) 2009-08-24 2015-08-04 Sirna Therapeutics, Inc. Segmented micro RNA mimetics
US20110052666A1 (en) 2009-09-03 2011-03-03 Medtronic, Inc. Compositions, Methods, and Systems for SIRNA Delivery
EP2496268A4 (en) 2009-11-06 2013-06-19 Univ Chung Ang Ind GENERATING SYSTEMS ON NANOPARTICLE BASIS
AU2010330814B2 (en) 2009-12-18 2017-01-12 Acuitas Therapeutics Inc. Methods and compositions for delivery of nucleic acids
JP2013515697A (ja) 2009-12-23 2013-05-09 マックスプランク−ゲセルシャフト・ツール・フェーデルング・デル・ヴィッセンシャフテン・エー・ファウ インフルエンザ標的
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
IL265674B2 (en) 2010-03-24 2024-05-01 Phio Pharm Corp Rana disorder in cutaneous and fibrotic symptoms
CN101845071B (zh) 2010-03-25 2012-02-01 北京欧凯纳斯科技有限公司 一种2’或3’偶联氨基酸的核苷衍生物、其制备方法及应用
JP5555940B2 (ja) 2010-04-14 2014-07-23 国立大学法人佐賀大学 増殖糖尿病網膜症の検出方法および予防・治療剤のスクリーニング方法
EP2562257A4 (en) 2010-04-19 2014-10-01 Riken PROCESS FOR STABILIZING FUNCTIONAL NUCLEIC ACIDS
ES2699630T3 (es) 2010-04-23 2019-02-12 Cold Spring Harbor Laboratory Novedosos ARNhc diseñados estructuralmente
ES2670017T3 (es) 2010-07-08 2018-05-29 Bonac Corporation Molécula de ácido nucleico de cadena simple para el control de la expresión de genes
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
WO2012012676A2 (en) 2010-07-22 2012-01-26 The University Of North Carolina At Chapel Hill Use of mir-29 for cell protection
ES2443346T3 (es) * 2010-08-03 2014-02-19 Bonac Corporation Molécula de ARN monocatenario que tiene esqueleto alicíclico que contiene nitrógeno
US8691782B2 (en) 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
EP2611927B1 (en) 2010-08-31 2018-08-01 Sirna Therapeutics, Inc. Novel single chemical entities and methods for delivery of oligonucleotides
BR112013013522A2 (pt) 2010-12-02 2019-09-24 Daiichi Sankyo Co Ltd polinucleotídeo ou um sal deste, composição farmacêutica, uso de um polinucleotídeo ou um sal deste, reagente, composição, e, método para produzir um composto
CN102559666B (zh) 2010-12-18 2013-12-25 中国科学院上海生命科学研究院 抑制植物病毒的人工miRNA及其构建和用途
EP3178932A1 (en) * 2011-02-03 2017-06-14 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
CN102784398B (zh) 2011-05-16 2014-06-18 南京大学 内皮抑素作为递送系统和化学合成的rna干扰分子组成的组合物及应用
JP6011945B2 (ja) 2011-05-20 2016-10-25 公一 中城 マイクロｒｎａ又はその発現系を含む組成物
EP2527440A1 (en) 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
JP2013055913A (ja) 2011-09-09 2013-03-28 Bonac Corp 遺伝子発現制御のための一本鎖ｒｎａ分子
WO2013077446A1 (ja) * 2011-11-26 2013-05-30 株式会社ボナック 遺伝子発現制御のための一本鎖核酸分子
JP2013153736A (ja) * 2012-01-07 2013-08-15 Bonac Corp ペプチド骨格を有する一本鎖核酸分子
WO2013103146A1 (ja) 2012-01-07 2013-07-11 株式会社ボナック アミノ酸骨格を有する一本鎖核酸分子
US9404108B2 (en) 2012-03-04 2016-08-02 Bonac Corporation Micro-RMA inhibitor
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
WO2013180038A1 (ja) 2012-05-26 2013-12-05 株式会社ボナック デリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子
EP2975938A4 (en) * 2013-03-15 2017-02-15 Ohio State Innovation Foundation Inhibitors of prmt5 and methods of their use
TWI727917B (zh) 2013-05-22 2021-05-21 美商阿尼拉製藥公司 ＴＭＰＲＳＳ６ｉＲＮＡ 組成物及其使用方法
WO2015093495A1 (ja) 2013-12-16 2015-06-25 株式会社ボナック ＴＧＦ－β１遺伝子発現制御のための一本鎖核酸分子
US10612020B2 (en) 2013-12-26 2020-04-07 Tokyo Medical University Artificial mimic miRNA for controlling gene expression, and use of same
CA2935022A1 (en) 2013-12-27 2015-07-02 Bonac Corporation Artificial match-type mirna for controlling gene expression and use therefor
WO2015099188A1 (ja) 2013-12-27 2015-07-02 株式会社ボナック 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
US10119140B2 (en) * 2014-04-18 2018-11-06 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods for enhancing or decreasing the levels of MIR124 and MIR29 in subjects with muscular dystrophy
US11142769B2 (en) 2015-03-27 2021-10-12 Bonac Corporation Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability
US20190010503A1 (en) 2015-12-29 2019-01-10 National University Corporation Hokkaido University Single-stranded nucleic acid molecule inhibiting expression of prorenin gene or prorenin receptor gene, and use thereof

Also Published As

Publication number Publication date
BR112017013664A2 (pt) 2018-03-13
WO2016104775A1 (ja) 2016-06-30
CN107109415B (zh) 2021-07-09
HK1244032A1 (en) 2018-07-27
JP6471176B2 (ja) 2019-02-13
MX381947B (es) 2025-03-11
JPWO2016104775A1 (ja) 2017-08-24
CN107109415A (zh) 2017-08-29
IL252880A0 (en) 2017-08-31
RU2740032C2 (ru) 2020-12-30
IL252880B (en) 2020-10-29
EP3239297A4 (en) 2018-07-25
AU2015368293A1 (en) 2017-07-13
KR20170098914A (ko) 2017-08-30
SG11201705223XA (en) 2017-07-28
US11027023B2 (en) 2021-06-08
RU2017126566A (ru) 2019-01-28
EP3239297A1 (en) 2017-11-01
AU2015368293B2 (en) 2021-07-22
EP3239297B1 (en) 2021-03-10
CA2971827A1 (en) 2016-06-30
ES2872527T3 (es) 2021-11-02
RU2017126566A3 (es) 2019-06-06
US20180326091A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
MX2017008587A (es) Mirna natural para controlar la expresion de gen y uso del mismo.
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
DOP2017000298A (es) Reguladores de nrf2
BR112016022841A2 (pt) cadeia j modificada
BR112018007017A2 (pt) polipeptídeos
MX2017016345A (es) Proteinas de fusion para inhibir la angiogenesis.
BR112017006137A2 (pt) formulação que contém biotensoativo
MX2016010675A (es) Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
MX376748B (es) Inhibidores del bromodominio.
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
DOP2016000073A (es) Composiciones y métodos para inhibir la expresión del gen alas1
BR112018075017A2 (pt) partículas de nicotina
MX379262B (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
MX2018000845A (es) Vector vírico orf recombinante.
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
CR20160448A (es) Nuevos derivados de piridina
CL2018000916A1 (es) Composiciones de silicato de zirconio de uso prolongado y métodos de uso de las mismas
BR112018003778A2 (pt) animal transgênico para produção de anticorpos que apresenta uma cadeia leve comum
ECSP17005294A (es) Composición adhesiva
DOP2020000104A (es) Métodos de uso y composiciones que contienen dulaglutida
PE20151878A1 (es) Fibra de madera acetilada
BR112019001621A2 (pt) solução aquosa cristaloide isotônica
MX2021004581A (es) Composiciones acuosas que comprenden omega nitrooxi-1-alcanoles.